Phase 3 Ovarian Cancer Trial, Recruiting NCT07546500 Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 3 Ovarian Cancer Trial, Recruiting

NCT07546500
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman aged 18 or older
  • You have been diagnosed with a specific type of ovarian, peritoneal, or fallopian tube cancer (high-grade serous type)
  • Your cancer can be measured on scans, following a standard set of measurement guidelines
  • You are generally active and able to care for yourself, with only minor limitations on daily activities (confirm with trial site)
  • A test of your tumor tissue has shown a specific protein called "cyclin E1" is present, using a special test approved for this trial
  • Your cancer has stopped responding to platinum-based chemotherapy (known as platinum-resistant disease)
  • You have received between 1 and 3 previous treatment regimens (or up to 4 if one of them included a drug called mirvetuximab)
  • You have previously received a drug called bevacizumab, if your doctors considered it appropriate for you
  • You have previously received a type of drug called a PARP inhibitor, if your cancer has a BRCA gene mutation or similar issue and your doctors considered it appropriate
  • You have previously received mirvetuximab, if your doctors considered it appropriate for you
  • Your blood counts and organ functions (such as kidneys and liver) are at acceptable levels during the screening period

Who may not be able to join:

  • You have had another cancer in the past 2 years, unless it was fully cured by surgery alone and has not come back (some exceptions may apply — confirm with trial site)
  • Your cancer never responded to platinum-based chemotherapy from the very start (rather than stopping working over time)
  • You have previously been treated with azenosertib or certain other specific targeted drugs (WEE1, ATR, CHK1/2, or PKMYT1 inhibitors) for this cancer
  • You have brain tumors that are causing symptoms or need immediate treatment (those with brain tumors that are not causing symptoms may still be eligible — confirm with trial site)
  • You have a serious kidney problem currently requiring medical intervention, or you have a urinary catheter or kidney drain in place
  • You have significant stomach or bowel problems that prevent you from swallowing pills, or you require nutrition given directly into a vein
  • There is evidence of a blockage in your small bowel, you were hospitalized for a bowel blockage in the past 3 months, or you have needed repeated fluid drainage from your abdomen or chest in the past 6 weeks
  • You have an active infection that has not been fully treated and cleared for at least 7 days before joining the trial
  • You have heart failure of a moderate to severe level (confirm with trial site)
  • You have a medical or mental health condition, or abnormal lab results, that the trial doctors believe could make participation unsafe or affect results
  • You were hospitalized in the 14 days before joining the trial
  • You had major surgery within the past 28 days
  • You received chemotherapy or certain other cancer treatments within the past 21 days (or within 5 half-lives of the drug, whichever is shorter)
  • You received radiation therapy within the past 21 days
  • You had a stem cell transplant within the past 3 months
  • You are currently taking another experimental drug as part of a different trial (within 28 days or 5 half-lives, whichever is shorter)
  • You are unable to stop taking certain medications, foods, or herbal supplements that are not allowed during this trial (confirm with trial site for the specific list)
  • You previously received radiation treatment covering a large portion (20% or more) of your bone marrow
  • You still have significant side effects (Grade 2 or higher) from previous cancer treatments, with some exceptions such as mild nerve problems, hair loss, or skin color changes
  • You have a weakened immune system, or you are HIV-positive and on anti-retroviral therapy
  • You have an active hepatitis B or hepatitis C infection
  • The trial doctors have determined for any other reason that the trial is not appropriate for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 858.263.4333

Australian sites

Site 1101, Randwick, New South Wales
Site 1102, Adelaide, South Australia
Site 1103, Nedlands,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Registry
ClinicalTrials.gov
Start date
17 April 2026
Est. completion
31 May 2028

Where this trial is recruiting

🇦🇺 Australia 🇧🇪 Belgium 🇨🇦 Canada 🇫🇷 France 🇩🇪 Germany 🇮🇪 Ireland 🇮🇹 Italy 🇵🇱 Poland 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan 🇺🇸 United States

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Progression free survival (PFS) per RECIST v1.1 as assessed by Investigator

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov